Search results for "AEM"

showing 10 items of 1006 documents

Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study

2015

Background: Incidence rates of lymphoma are usually higher in men than in women, and oestrogens may protect against lymphoma. Methods: We evaluated occupational exposure to endocrine disrupting chemicals (EDCs) among 2457 controls and 2178 incident lymphoma cases and subtypes from the European Epilymph study. Results: Over 30 years of exposure to EDCs compared to no exposure was associated with a 24% increased risk of mature B-cell neoplasms (P-trend=0.02). Associations were observed among men, but not women. Conclusions: Prolonged occupational exposure to endocrine disruptors seems to be moderately associated with some lymphoma subtypes. © 2015 Cancer Research UK. All rights reserved.

OncologyMaleendocrine systemCancer Researchmedicine.medical_specialtyanimal structuresLymphomaEpidemiologyJob-exposure matrixchemicalsEndocrine Disruptors03 medical and health sciences0302 clinical medicineSex FactorsSex factorsRisk FactorsInternal medicinehemic and lymphatic diseasesOccupational ExposuremedicineOccupational exposure - endocrine disrupting chemicals (EDCs) - lymphoma riskEndocrine systemHumansurogenital systembusiness.industryIncidence (epidemiology)IncidenceCase-control studynutritional and metabolic diseasespesticidesmedicine.disease030210 environmental & occupational health3. Good healthLymphomaEuropeOccupational DiseasessolventsOncologyMulticenter study030220 oncology & carcinogenesisCase-Control StudiesImmunologyleukaemiaalkylphenolsFemaleOccupational exposurebusinesshormones hormone substitutes and hormone antagonists
researchProduct

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable res…

2021

Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH).

OncologyMalep13)/TCF3-PBX1Neoplasm ResidualOncogene Proteins FusionCytogenetic alterationsmedicine.medical_treatmentDiseaseTranslocation Genetichemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocolst(1;19)(q23;p13)/TCF3-PBX1Cumulative incidenceCitogenètica humanaNeoplasm MetastasisLeucèmia limfoblàstica - TractamentHuman cytogeneticsLeukemiaAcute lymphoblastic leukaemiaRemission InductionLeucèmiaDisease ManagementHematologyMiddle AgedPrognosisHaematopoiesismedicine.anatomical_structureTreatment OutcomeChromosomes Human Pair 1TCF3:Other subheadings::Other subheadings::/therapy [Other subheadings]FemaleStem cell:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor B-Cell Lymphoblastic Leukemia-Lymphoma [DISEASES]Adultmedicine.medical_specialtyPronòstic mèdicAdolescentQuimioteràpia combinadaYoung AdultInternal medicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAdultsHumansB cell19)(q23Neoplasm Staging:neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células B precursoras [ENFERMEDADES]business.industryacute lymphoblastic leukaemia adults cytogenetic alterations prognosis t(1:Otros calificadores::Otros calificadores::/terapia [Otros calificadores]ImmunotherapyChromosome BandingTransplantationt(1Avaluació de resultats (Assistència sanitària)businessChromosomes Human Pair 19British journal of haematologyReferences
researchProduct

A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at T…

2021

Molecular testing of the BCR-ABL1 transcript via real-time quantitative-polymerase-chain-reaction is the most sensitive approach for monitoring the response to tyrosine-kinase-inhibitors therapy in chronic myeloid leukaemia (CML) patients. Each stage of the molecular procedure has been standardized and optimized, including the total white blood cells (WBCs) and RNA isolation methods. Here, we compare the performance of our current manual protocol to a newly semiautomatic method based on the Biomek i-5 Automated Workstations integrated with the CytoFLEX Flow Cytometer, followed by the automatic QIAsymphony system to facilitate high-throughput processing samples and reduce the hands-on time a…

OncologyMedicine (General)medicine.medical_specialtyBCR-ABL1/ABL1Q-PCRbusiness.industrychronic myeloid leukaemiaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)SARS-CoV-2 infectionClinical BiochemistrySample processingmolecular responseBCR-ABL1/ABL1ISChronic myeloid leukaemiaArticle<i>BCR-ABL1/ABL1<sup>IS</sup></i>R5-920Real-time polymerase chain reactionInternal medicinehemic and lymphatic diseasesMolecular ProcedureISmedicineRNA extractionbusinessDiagnostics
researchProduct

Incidence, survival and prevalence of myeloid malignancies in Europe.

2012

Abstract Background The Surveillance of Rare Cancers in Europe (RARECARE) project aims at increasing knowledge of rare cancers in Europe. This manuscript describes the epidemiology of myeloid malignancies (MMs), taking into account the morphological characterisation of these tumours. Methods We used data gathered by RARECARE on cancer patients diagnosed from 1995 to 2002 and archived in 64 European population-based cancer registries, followed up to 31st December 2003 or later. Results The overall annual crude incidence of MMs was 8.6 per 100,000. Acute myeloid leukaemia (AML) and myeloproliferative neoplasms (MPN) were most common, with incidence rates of 3.7 and 3.1 per 100,000 year respec…

OncologyMyeloidMaleCancer ResearchMyeloidSurvivalChronic myelomonocytic leukaemiaCancer registry Incidence Prevalence Survival Myeloid malignancies Acute myeloid leukaemia Myelodysplastic syndrome Chronic myeloid leukaemia Chronic myelomonocytic leukaemiaImmunophenotypingEpidemiologyPrevalenceChildLeukemiaIncidence (epidemiology)IncidenceMyeloid malignanciesCancer registryMiddle AgedEuropeLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureOncologyChild PreschoolMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityMyelodysplastic Syndromes/epidemiology/mortalityFemaleAdultmedicine.medical_specialtyAdolescentAcute myeloid leukaemiaNOEurope/epidemiologyInternal medicinemedicinecancer Incidence; survival and prevalence; myeloid malignanciesHumansPreschoolChronic myeloid leukaemiaddc:613AgedMyeloproliferative Disorders/epidemiology/mortalityMyeloproliferative Disordersbusiness.industryMyelodysplastic syndromesInfant NewbornCancerInfantcancer Incidencemedicine.diseaseNewbornMyelodysplastic-Myeloproliferative DiseasesCancer registrysurvival and prevalenceMyelodysplastic SyndromesImmunologyAcute/epidemiology/mortalitybusinessMyelodysplastic syndrome
researchProduct

G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group,…

2020

IntroductionAmyotrophic lateral sclerosis (ALS) is a fatal progressive neurological disorder characterised by a selective degeneration of motor neurons (MNs). Stem cell transplantation is considered as a promising strategy in neurological disorders therapy and the possibility of inducing bone marrow cells (BMCs) to circulate in the peripheral blood is suggested to investigate stem cells migration in degenerated ALS nerve tissues where potentially repair MN damage. Granulocyte-colony stimulating factor (G-CSF) is a growth factor which stimulates haematopoietic progenitor cells, mobilises BMCs into injured brain and it is itself a neurotrophic factor for MN. G-CSF safety in humans has been de…

Oncologyamyotrophic lateral sclerosismedicine.medical_specialtyFilgrastimFilgrastimPlacebocGSF ALS Clinical triallaw.inventionrandomised clinical trialClinical Trials Phase II as TopicDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHumansMulticenter Studies as Topic1506Amyotrophic lateral sclerosisRandomized Controlled Trials as Topicbusiness.industryRGeneral Medicineamyotrophic lateral sclerosis; GCS-F; haematopoietic stem cells; randomised clinical trialmedicine.diseaseGranulocyte colony-stimulating factorTransplantationClinical trialGCS-FNeurologyItalyTolerabilityQuality of Life1713MedicineSettore MED/26 - Neurologiabusinesshaematopoietic stem cellsmedicine.drugBMJ Open
researchProduct

GM-CSF in a Double-Blind Randomized Placebo-Controlled Trial in Therapy of Adult Patients with De Novo Acute Myeloid Leukemia

1994

Despite the fact that 60%–70% of patients with de novo acute myeloblastic leukemia (AML) achieve a complete remission (CR) of the disease only about 20%–30% of the patients remain in long term remission and are probably cured [1,2]. These rather disappointing long-term results argue in favor of an even more intensive induction and post-remission therapy. This intention is, however, at time limited by therapy associated toxicity. Especially haematotoxicity seems to be the limiting factor in that patients with profound neutropenia are at high risk of developing fatal infectious complications [3]. In this context haematopoietic growth factors, such as granulocyte-macrophage colony-stimulating …

Oncologymedicine.medical_specialtyAcute myeloblastic leukemiabusiness.industryPlacebo-controlled studyMyeloid leukemiaNeutropeniamedicine.diseaseGranulocyte colony-stimulating factorHaematopoiesisPharmacotherapyInternal medicineImmunologymedicineCytarabinebusinessmedicine.drug
researchProduct

Erythropoietin: effects on life expectancy in patients with cancer-related anaemia

2006

ABSTRACTAnaemia is common in patients with cancer and has a detrimental impact on the quality of life. Anaemia has also been shown to reduce survival in patients with cancer. Tumour hypoxia resulting from the reduced oxygen carrying capacity of the blood in anaemic patients has been hypothesised to be a major contributor to this reduced survival. Several studies have shown that tumour hypoxia reduces the effectiveness of anticancer therapies including standard radiotherapy and some types of chemotherapy, and is associated with tumour progression. Moreover, preclinical data have demonstrated that erythropoietic protein therapy may delay tumour progression by improving tumour oxygenation. Mos…

Oncologymedicine.medical_specialtyChemotherapyCancer-related anaemiabusiness.industrymedicine.medical_treatmentGeneral MedicineHypoxia (medical)medicine.diseaseRadiation therapyBreast cancerErythropoietinInternal medicineImmunologymedicineLife expectancyIn patientmedicine.symptombusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study

2021

Background: The purpose of the study was to evaluate secondary stroke prevention in Poland and its association with sociodemographic factors, place of residence, and concomitant cardiovascular risk factors. Material and methods: From all patients in LIPIDOGRAM2015 Study (n = 13,724), 268 subjects had a history of ischaemic stroke and were included. Results: 165 subjects (61.6%) used at least one preventive medication. Oral antiplatelet and anticoagulation agents were used by 116 (43.3%) and 70 (26.1%) patients, respectively. Only 157 (58.6%) participants used lipid-lowering drugs, and 205 (76.5%) were treated with antihypertensive drugs. Coronary heart disease (CHD) and dyslipidaemia were a…

Oral anticoagulant drugsmedicine.medical_specialtyRMArticleLifestyle modificationOral antiplatelet drugsInternal medicineIschaemic strokemedicineMyocardial infarctioncardiovascular diseasesSecondary stroke preventionStrokePrimary health careoral anticoagulant drugssecondary stroke preventionbusiness.industryRAtrial fibrillationoral antiplatelet drugsGeneral Medicinemedicine.diseaseR1Coronary heart diseaseprimary health careStroke preventionConcomitantMedicinebusiness
researchProduct

Estimation of tensile properties of the Achilles tendon in haemophilic arthropathy of the ankle: case study

2015

OrthodonticsAchilles tendonHaemophilic arthropathymedicine.anatomical_structurebusiness.industryUltimate tensile strengthmedicineHematologyGeneral MedicineAnklebusinessGenetics (clinical)Haemophilia
researchProduct

Experimental investigation and modeling of diffusion dialysis for HCl recovery from waste pickling solution

2019

Abstract Hydrochloric acid recovery from pickling solutions was studied by employing a batch diffusion dialysis (DD) laboratory test-rig equipped with Fumasep membranes. The effect of main operating parameters such as HCl concentration (0.1–3 M) and the presence of Fe2+ (up to 150 g/l) was investigated to simulate the system operation with real industrial streams. The variation of HCl, Fe2+ and water flux was identified. When only HCl is present, a recovery efficiency of 100% was reached. In the presence of FeCl2, higher acid recovery efficiencies, up to 150%, were observed due to the so-called “salt effect”, which promotes the passage of acid even against its concentration gradient. A 7% l…

OsmosisIndustrial waste recoverySettore ING-IND/26 - Teoria Dello Sviluppo Dei Processi ChimiciEnvironmental EngineeringMaterials science0208 environmental biotechnologyAnalytical chemistryHydrochloric acid02 engineering and technology010501 environmental sciencesManagement Monitoring Policy and Law01 natural sciencesDiffusion dialysiDiffusionchemistry.chemical_compoundRenal DialysisPicklingWaste Management and Disposal0105 earth and related environmental sciencesLeakage (electronics)AEMSalt effectModelingGeneral Medicine6. Clean water020801 environmental engineeringMembranechemistryHydrochloric AcidConcentration gradientPickling proceAcidsJournal of Environmental Management
researchProduct